跳至主要内容
临床试验/NL-OMON39160
NL-OMON39160
已完成
不适用

Systemic manifestation and co-morbidity in COPD are associated with circulating markers of aging - COPD as a syndrome of accelerated aging

niversiteit Maastricht0 个研究点目标入组 800 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
niversiteit Maastricht
入组人数
800
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational invasive

研究者

入排标准

入选标准

  • For the COPD patients: diagnosis of COPD according to the American Thoracic Society (ATS) GOLD guidelines (FEV1 \< 80% predicted and FEV1/FVC \< 70% \[18]; both male and female, age\-range from 45 to 75 y; no respiratory tract infection or exacerbation of the disease for \< 4 weeks before the study; capable of providing informed consent.
  • For the healthy subjects: subjects without the objectively diagnosed diseases assessed in the present study: COPD, untreated diabetes mellitus type II, severe and untreated osteoporosis, severe renal failure or heart failure. Both male and female, age\-range from 45 to 75 y will be included in the study.

排除标准

  • For the COPD patients and controls: any kind of carcinogenic pathology \<5 y before study participation; chronic use of oral corticosteroids \> 10mg/day; participation in any other studies involving investigational or marketed products concomitantly or \< 4 weeks prior to entry into the study, investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.

结局指标

主要结局

未指定

相似试验